Alivus Life Sciences Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 years The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 9024 crore as compare to the Sep '25 revenue of ₹ 9158 crore. This represent the decline of -1.46% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 2158 crore as compare to the Sep '25 ebitda of ₹ 2340 crore. This represent the decline of -7.76% The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 1189 crore over 7 quarters. This represents a CAGR of -8.60% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

FAQs for the comparison of Alivus Life Sciences Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Dr Reddys Laboratories Ltd?

Market cap of Alivus Life Sciences Ltd is 13,788 Cr while Market cap of Dr Reddys Laboratories Ltd is 109,381 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Alivus Life Sciences Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Dr Reddys Laboratories Ltd?

As of May 6, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1123.45. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1310.5.

How do dividend payouts of Alivus Life Sciences Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.